A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

计划入组 40 人 · 首次发布于 2025 年 2 月 17 日

The clonoSEQ® Watch Registry

计划入组 465 人 · 首次发布于 2020 年 9 月 11 日

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

计划入组 65 人 · 首次发布于 2024 年 7 月 3 日

ADAPTOGENICS HEALT

United States

Adaptive Biotechnologies' clonoSEQ MRD Test Featured in Record 89 Abstracts at ASH 2025

Medicare Expands Coverage of Adaptive Biotechnologies' clonoSEQ for Mantle Cell Lymphoma

Adaptive Biotechnologies Integrates clonoSEQ MRD Testing into Flatiron Health's OncoEMR Platform